Michio Otsuki    Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine    Position   Professor and Division head
Article types	Case report
Language	English
Peer review	Peer reviewed
Title	Treatment of Mitochondrial Diabetes with a Peroxisome Proliferator-activated Receptor (PPAR)-gamma Agonist
Journal	Formal name：Internal Medicine Abbreviation：Intern Med ISSN code：09182918
Domestic / Foregin	Domestic
Volume, Issue, Page	55(9),pp.1143-1147
Author and coauthor	Ninomiya, H. Hirata, A. Kozawa, J. Nakata, S. Kimura, T. Kitamura, T. Yasuda, T. Otsuki, M. Imagawa, A. Kaneto, H. Funahashi, T. Shimomura, I.
Publication date	2016
Summary	The 3243 A>G mutation in mitochondrial DNA is the most common cause of monogenic diabetes mellitus in Japan. A 45-year-old woman with mitochondrial diabetes and significant insulin resistance presented with hypoadiponectinemia despite a normal amount of visceral fat. Three months of treatment with pioglitazone (PIO) improved her blood glucose profile and response to the 75-g oral glucose tolerance test. These changes were accompanied by the amelioration of her insulin resistance and the impairment of early-phase insulin secretion. Her serum adiponectin levels increased to the normal range. In this case of mitochondrial diabetes, PIO was effective for glycemic control.
DOI	10.2169/internalmedicine.55.4418
Document No.	27150869